Drug Trial Radar · NCT03349060
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
387
Actual
Start
Dec 7, 2017
Primary completion
Mar 26, 2019
Study completion Mar 26, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.
Conditions
- Dermatitis, Atopic
Interventions
PF-04965842 100 mgDrug
PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
PF-04965842 200 mgDrug
PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
PlaceboDrug
Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12Time frame: Baseline, Week 12
- Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response of >=75 Percent (%) Improvement From Baseline at Week 12Time frame: Baseline, Week 12
Locations
88 sites in 8 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
California Dermatology & Clinical Research Institute
Encinitas, California
Rady Children's Hospital - San Diego/University of California, San Diego
San Diego, California
TCR Medical Corporation
San Diego, California
Clinical Science Institute
Santa Monica, California
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida
Olympian Clinical Research
Largo, Florida
Forward Clinical Trials, Inc.
Tampa, Florida
Meridian Clinical Research, LLC
Savannah, Georgia
NorthShore University HealthSystem Dermatology Clinical Trials Unit
Skokie, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Dawes Fretzin Dermatology Group, LLC
Indianapolis, Indiana
Tufts Medical Center
Boston, Massachusetts
Henry Ford Medical Center, New Center One
Detroit, Michigan
Somerset Skin Centre
Troy, Michigan
MediSearch Clinical Trials
Saint Joseph, Missouri
Lynn Health Science Institute
Oklahoma City, Oklahoma
Vital Prospects Clinical Research Institute, P.C.
Tulsa, Oklahoma
Oregon Health & Science University
Portland, Oregon
Medical University of South Carolina Investigational Drug Services
Charleston, South Carolina
MUSC SCTR Research Nexus Clinic and Laboratory
Charleston, South Carolina
Arlington Research Center, Inc.
Arlington, Texas
The University of Texas Health Science Center Houston
Houston, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Virginia Clinical Research, Inc.
Norfolk, Virginia
Pace Dermatology Associates
Lakewood, Washington
MultiCare Allenmore Hospital
Tacoma, Washington
MultiCare Institute for Research and Innovation
Tacoma, Washington
Pace Dermatology Associates
Tacoma, Washington
Australian Clinical Research Network (ACRN)
Maroubra, New South Wales, Australia
Spectrum Medical Imaging
Maroubra, New South Wales, Australia
Queensland X-Ray
Upper Mount Gravatt, Queensland, Australia
Veracity Clinical Research Pty Ltd
Woolloongabba, Queensland, Australia
Emeritus Research
Camberwell, Victoria, Australia
Skin and Cancer Foundation Inc
Carlton, Victoria, Australia
Melbourne Radiology Clinic
East Melbourne, Victoria, Australia
Sinclair Dermatology
East Melbourne, Victoria, Australia
The Royal Children's Hospital
Parkville, Victoria, Australia
Bridge Road Imaging
Richmond, Victoria, Australia
Kirk Barber Research
Calgary, Alberta, Canada
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.